Home / Business and Economy / Cipla Partners Pfizer for Wider Drug Access
Cipla Partners Pfizer for Wider Drug Access
19 Dec
Summary
- Cipla gains exclusive rights to market four Pfizer brands in India.
- Pfizer will continue manufacturing and supplying the specified medicines.
- This marks the first collaboration between Pfizer and Cipla in India.
Cipla Ltd. has secured an exclusive agreement with Pfizer India, positioning it to market, distribute, and sell four key Pfizer brands throughout India. This strategic alliance, announced recently, empowers Cipla with sole rights for prominent medications.
Under this pact, Cipla will manage the distribution of the cough syrups Corex Dx and Corex LS, the anti-inflammatory drug Dolonex, the proton pump inhibitor Neksium, and the antibiotic Dalacin C. Pfizer will maintain its role in manufacturing and supplying these essential medicines to Cipla for the Indian market, ensuring continuity and quality.
This collaboration signifies a significant step for both companies, marking their first partnership in India. The union is expected to enhance patient access to Pfizer's trusted portfolio by combining it with Cipla's deep-rooted distribution network and market expertise, addressing the healthcare needs of millions across the nation.
